Contrary to the CLL-IPI, the prognostic value of B2M alone was also maintained in CLL patients diagnosed and potentially treated frontline in the era of targeted agents (2014–2022, p = 0.03). The gene discussed is B2M; the disease is B-cell chronic lymphocytic leukemia.